Introduction
============

Functional gastrointestinal disorders (FGIDs) are a group of gastrointestinal (GI) disorders that include various combinations of chronic or recurrent GI symptoms not explained by structural or biochemical abnormalities.[@b1-jnm-21-320] Functional dyspepsia (FD) and irritable bowel syndrome (IBS) are among the most widely recognized FGIDs. It is characteristic of the FGIDs that each entity has no specific objective findings, and that they overlap with each other. Therefore, these entities are syndromes, and their diagnosis and treatment are similar. Diagnosis of FGIDs is based on patients' self-reported symptoms. Therefore, the definition of the symptoms may differ by countries and geographic areas. The pathophysiology of FGIDs is recently becoming clearer. The definition and the diagnostic criteria have been revised, and the diagnostic system is becoming more systematic.[@b1-jnm-21-320],[@b2-jnm-21-320] In this review, the epidemiology of FGIDs in Japan and in the world is reviewed.

Prevalence
==========

It is well-known that dyspeptic symptoms occur with organic diseases such as reflux esophagitis, gastroduodenal ulcer, and cancer. However, dyspepsia without organic disease is more prevalent in patients who seek medical care.[@b3-jnm-21-320] El-Serag et al[@b4-jnm-21-320] performed a meta-analysis of the literature published between 1976 and 2000 that showed the frequency of dyspepsia to be 10--40%; however, this frequency was 5--12% when concurrent symptoms including heartburn were excluded. In the Rome II definition published in 1999,[@b2-jnm-21-320] reflux symptoms were excluded from the definition of FD, and when IBS symptoms were present, FD was diagnosed as IBS. Therefore, whether heartburn or IBS is included easily affects the prevalence of FD. Kawamura et al[@b5-jnm-21-320] reported that the prevalence of FD defined by Rome II in subjects undergoing a health check-up was 13% when organic diseases were excluded. Shaib et al[@b6-jnm-21-320] also reported that the prevalence of FD was 15% when organic diseases were excluded by endoscopy and when subjects with gastroesophageal reflux disease symptoms were excluded. In a report from England, when endoscopy was performed in 20% of patients to exclude organic diseases, the prevalence of FD was thought to be 11.5%.[@b7-jnm-21-320] In a report from Norway, when endoscopy was performed in almost all patients, the prevalence of FD was 14.7%.[@b8-jnm-21-320]

The prevalence of uninvestigated dyspepsia or FD in the general population, diagnosed by Rome III criteria, which has been used from 2006, has been reported to be 5.3--20.4% ([Table 1](#t1-jnm-21-320){ref-type="table"}).[@b9-jnm-21-320]--[@b22-jnm-21-320] Hongo et al[@b23-jnm-21-320] reported that organic lesions were found in only 9% of patients examined by endoscopy because of dyspepsia symptoms. Furthermore, among those without any specific lesions detected on endoscopy, GI symptoms were resolved within one week after the endoscopy in 28% of patients before initiating medication. Okumura et al[@b3-jnm-21-320] reported that 21% of patients who visited a university hospital with abdominal symptoms had FD.

We also recently performed an Internet survey using a registered panel in Japan to elucidate the prevalence of dyspepsia and childhood abuse history in the population.[@b24-jnm-21-320] When we estimated the prevalence of dyspepsia using our age-stratified subjects' data and the Japanese population census (<http://www.stat.go.jp/english/data/kokusei/index.htm>), the prevalence of dyspepsia in Japan was estimated to be 21.9%, and the percentage of subjects who consulted a medical institute was only 5.7% of the Japanese population.[@b25-jnm-21-320] In other words, only one-fourth of dyspeptic subjects visited a medical institute. As the usefulness of an Internet survey was not validated, these conclusions are not firm. With the recent advances of Internet applications, online surveys may be useful as a tool to estimate the prevalence, especially in the general population.

IBS is a functional bowel disorder in which abdominal pain or discomfort is associated with defecation or a change in bowel habit and with features of disordered defecation.[@b26-jnm-21-320] In a systematic review of IBS in North America, the prevalence of IBS ranged from 3% to 20%, with most estimates ranging from 10% to 15%.[@b27-jnm-21-320] Reports from Japan indicated that the prevalence of IBS defined by Rome II was 6.1% to 35.5%. In reports using Rome III criteria, the prevalence of IBS was 1.1% to 29.2% ([Table 2](#t2-jnm-21-320){ref-type="table"}).[@b11-jnm-21-320],[@b12-jnm-21-320], [@b14-jnm-21-320],[@b15-jnm-21-320],[@b18-jnm-21-320],[@b21-jnm-21-320],[@b22-jnm-21-320],[@b28-jnm-21-320]--[@b38-jnm-21-320] Miwa[@b29-jnm-21-320] reported that the prevalence of IBS was 13.1% (male 10.7% and female 15.5%), and when the prevalence of IBS was evaluated using Rome II criteria in the same cohort, IBS prevalence was 9.8%, suggesting that the Rome III criteria are better for picking up more masked IBS cases.

The prevalences of FGIDs other than FD and IBS in the general population were investigated in few studies. Only two reports investigated the prevalence of functional bowel disorders, including functional abdominal bloating, functional constipation (FC), functional diarrhea, unspecified functional bowel disorder (UFBD), and functional abdominal pain syndrome (FAPS) defined by Rome III criteria ([Table 3](#t3-jnm-21-320){ref-type="table"}).[@b14-jnm-21-320],[@b33-jnm-21-320] These two reports showed female predominance of FC and UFBD. Among these FGIDs, UFBD, uninvestigated dyspepsia, and FC were common, and FAPS was less common than other FGIDs. This is consistent with a report of hospital outpatients in Japan.[@b39-jnm-21-320]

The investigation environment, the definition of symptom duration, and the accuracy of excluding organic diseases have all been identified as factors affecting the prevalence of FGIDs. In the Rome II definition,[@b2-jnm-21-320] the symptom duration of FD and IBS was defined as at least 12 weeks during the preceding 12 months, and in Rome III,[@b1-jnm-21-320] at least 3 months with symptom onset at least 6 months prior to diagnosis, which implies that the duration of symptoms can easily change the prevalence. In Japan, people who have symptoms visit a medical institute within less than 6 months of symptom onset because access to facilities is easy.[@b40-jnm-21-320],[@b41-jnm-21-320] Thus, the duration of symptoms does not match the criteria of FD in the majority of cases.[@b40-jnm-21-320],[@b42-jnm-21-320] Furthermore, although structural or biochemical disorders should be excluded, they are not easy to exclude in a survey of the general population. In a large-scale analysis of the prevalence of FGIDs, it is not easy to perform examinations of all subjects. In general practice, the availability of examinations may be limited and different compared to those in a large hospital or university hospital. The characteristics of patients are also different in primary care and tertiary care settings. When new patients who visited primary clinics and tertiary care hospitals with gastrointestinal symptoms for more than 6 months in Korea were analyzed, the prevalences of FD and IBS defined by Rome III criteria were 46.0% and 40.2%, respectively.[@b43-jnm-21-320] On the other hand, when patients who visited a general hospital in Japan were analyzed, the prevalences of FD and IBS defined by Rome III criteria were 2.1% and 2.4%, respectively.[@b39-jnm-21-320] Therefore, when we evaluate the prevalence of FGIDs, we should take the background characteristics of the analyzed subjects into account.

Epidemiological Factors
=======================

Sex/Subtype/Age
---------------

The prevalence of abdominal symptoms in a population-based study in the USA showed no significant differences between men and women.[@b44-jnm-21-320] Even in Japan, no difference in the prevalence of non-ulcer dyspepsia has been reported. The definition of dyspepsia may easily affect the prevalence, and the surveys using Rome II or other than Rome definitions mostly showed no differences between men and women in the prevalence of dyspepsia.[@b3-jnm-21-320],[@b45-jnm-21-320]However, Schlemper et al[@b46-jnm-21-320] assessed dyspeptic symptoms present during more than 7 days per 3 months in a working population and reported that, in Japanese men and women, the non-ulcer dyspepsia rates were 11% and 26%, while in The Netherlands, they were 12% and 21%, respectively, indicating that dyspepsia is more prevalent in women. A report from Belgium also showed that female FD was more prevalent in consecutive patients who visited a general gastroenterology outpatient clinic.[@b47-jnm-21-320] In a population-based study of the Icelandic population, FD was diagnosed in 12.3% of males and 20.2% of females, and it was significantly more common in females.[@b47-jnm-21-320],[@b48-jnm-21-320] Furthermore, in a systematic review by Ahlawat et al,[@b49-jnm-21-320] dyspepsia had a different pattern of symptoms in men and women.[@b49-jnm-21-320] In this manner, study area, type of survey, and the definition of FD might easily affect the results.

Approximately two-thirds of IBS patients are female, and the prevalence of IBS in females is thought to be 14--24%.[@b50-jnm-21-320] The potential role of sex hormones in sex differences in the epidemiology of IBS patients has been proposed based on the female predominance, as well as the correlation between IBS symptoms and hormonal status.[@b51-jnm-21-320] Even in Japanese studies, female predominance has been reported.[@b52-jnm-21-320],[@b53-jnm-21-320] Recent reports of FD and IBS defined by Rome III criteria also indicated a female predominance in Japan and other countries ([Tables 1](#t1-jnm-21-320){ref-type="table"} and [2](#t2-jnm-21-320){ref-type="table"}).

Regarding the subtype prevalence of FD defined by Rome II criteria, in Japanese health check-up subjects, dyspeptic symptoms were present in 17%, and approximately 10% of subjects complained of dysmotility-like dyspepsia corresponding to post-prandial distress syndrome (PDS), and approximately 4% of subjects complained of ulcer-like dyspepsia corresponding to epigastric pain syndrome (EPS).[@b54-jnm-21-320] Even in a recent report using Rome III criteria, PDS was more prevalent than EPS in Sweden, China, and Japan ([Table 1](#t1-jnm-21-320){ref-type="table"}).[@b16-jnm-21-320],[@b17-jnm-21-320],[@b55-jnm-21-320] However, a report from Italy indicated that EPS was more prevalent than PDS ([Table 1](#t1-jnm-21-320){ref-type="table"}).[@b13-jnm-21-320] These differences by geographic areas were also reported in a review of dyspepsia defined by Rome II criteria.[@b56-jnm-21-320] Therefore, considering these epidemiological differences of FD subtypes between Western countries and East Asia, the optimal treatment strategies for FD may differ among countries.

On the other hand, with respect to the subtype prevalence of IBS, IBS with diarrhea (IBS-D) is more predominant than IBS with constipation (IBS-C) ([Table 2](#t2-jnm-21-320){ref-type="table"}). The subtype prevalence of IBS is characterized by male predominance in IBS-D and female predominance in IBS-C.[@b52-jnm-21-320],[@b57-jnm-21-320] In a meta-analysis, women were at slightly higher risk for IBS than men.[@b58-jnm-21-320] When the prevalence of IBS and its subtypes was determined using Rome III criteria, the prevalences of IBS subtypes in Japanese were as follows: IBS-D, male 47% and female 17%; IBS-C, male 9% and female 34%; and mixed IBS (IBS-M), male 44% and female 49%.[@b29-jnm-21-320] IBS is most prevalent in patients 20 to 30 years old, and this prevalence decreases with age.[@b58-jnm-21-320] In a Japanese study of medical and nursing students, the prevalence of IBS was 35.5%, and students with IBS symptoms were more prone to have anxiety and depression, indicating that stress is involved in the development of IBS symptoms.[@b59-jnm-21-320] Furthermore, high socioeconomic status may be related to the prevalence of IBS, but this is not conclusive.[@b58-jnm-21-320]

Race/Geographic Area
--------------------

The domestic international gastroenterology surveillance study (DIGEST) investigated the prevalence and economic/quality-of-life impact of uninvestigated dyspepsia over 3 months and found that 41% of the general population had dyspepsia in 7 international sites, 60% in the USA, and 26% in Japan, indicating that the Japanese prevalence is relatively low.[@b60-jnm-21-320] On the other hand, reports of dyspepsia prevalence in the general population from Australia and China showed that 24.4% and 23.5% had dyspepsia, respectively.[@b61-jnm-21-320],[@b62-jnm-21-320] Although these data indicate that the prevalence differs among geographic areas, the studies may not have completely excluded organic diseases, and the definition of symptom frequency was different in the reports. Furthermore, the interpretation of symptoms may be subtly different in countries and geographic areas. As the definition of FGIDs differs in the Rome III criteria, the Rome II criteria, and previous definitions, it is not easy to compare the data directly.

In an analysis performed in the USA, the prevalence of FD was not different by race.[@b6-jnm-21-320] On the other hand, race may affect the development of IBS. The prevalence of IBS was 13.1% in Caucasians and 7.9% in Africans.[@b63-jnm-21-320] A meta-analysis of the global prevalence of IBS indicated that the prevalence of IBS varied among countries.[@b58-jnm-21-320]

Food
----

FD patients do not usually eat their meals 3 times a day, and the intakes of fat, glucose, and vitamin C are less in female FD patients.[@b64-jnm-21-320] However, it is also reported that the patterns of food and meal intake were not different,[@b65-jnm-21-320] indicating that the relationship between food and FD is not clear. Since it is not known if the difference in the food intake pattern in controls and FD is the result of attempting to prevent the development of symptoms or the cause of symptoms, further studies are needed to elucidate the causal relationship.

In IBS patients, food may exacerbate symptoms. Milk, wheat, eggs, and foods high in salicylates or amines are identified as causes of exacerbation of IBS symptoms.[@b66-jnm-21-320] Japanese IBS patients have significantly more irregular meal habits.[@b67-jnm-21-320] Recent studies from Australia and the United Kingdom (UK) indicated that dietary restriction of fermentable oligo-, di-, and monosaccharides and polyols (FODMAPs) is effective for the treatment of IBS.[@b68-jnm-21-320]--[@b71-jnm-21-320] Khan et al[@b72-jnm-21-320] summarized the clinical efficacy of a low-FODMAP diet in IBS patients. A low-FODMAP diet improved self-assessed satisfaction with stool consistency in both IBS-D and IBS-C subgroups, but not in healthy controls.[@b71-jnm-21-320] However, further studies are needed to evaluate the mechanisms of these effects. Since the daily diet differs among countries, the efficacy of a low-FODMAP diet should be evaluated in each country.

Lactose intolerance and IBS can occur at the same time in a person, but they are separate conditions that should be treated differently. A recent National Institutes of Health (NIH) conference defined "lactose intolerance as the onset of GI symptoms following a blinded, single-dose challenge of ingested lactose by an individual with lactose malabsorption, which are not observed when the person ingests an indistinguishable placebo."[@b73-jnm-21-320] The risk of lactose intolerance is related to the dose of lactose ingested and intestinal gas production and is increased in patients with IBS-D.[@b74-jnm-21-320] Although it is not easy to exclude lactose intolerance in daily clinical practice, it should not be included in IBS.

Genetics and Early Life Events
------------------------------

After the unveiling of whole human genome sequences in 2004, it became clear in many diseases, including malignant tumors, hypertension, and psychosomatic diseases, that single nucleotide polymorphisms of genes were involved even in drug metabolism. In other words, when a single nucleotide is different, translation of a protein or function can easily be changed, and these changes may affect the development of diseases and treatment effectiveness.

Even in FGIDs, these gene polymorphisms are involved in the development of diseases. Syndromes of FGIDs had been thought to be difficult to explain with gene polymorphisms as the pathophysiology. However, it recently became clear that not only environmental factors, but also genetics are involved in the development of FGIDs.[@b75-jnm-21-320],[@b76-jnm-21-320] Levy et al[@b75-jnm-21-320] analyzed 6060 twin pairs, and concordance for IBS was significantly greater in monozygotic (17.2%) than in dizygotic (8.4%) twins, supporting a genetic contribution to IBS. Even in FD patients, familial aggregations have been identified.[@b77-jnm-21-320] As the gene polymorphisms that are involved in the development of IBS, *5-HTTLPR* of serotonin transporter (SERT), *TNF-*α, and *IL-10* have been suggested.[@b78-jnm-21-320],[@b79-jnm-21-320] Furthermore, *TLR9*, *IL-6*, and *CDH1* variants are independent risk factors of post-infectious IBS.[@b80-jnm-21-320] The C/C genotype of the −42C\>T polymorphism in *HTR3A*, compared with T carrier status, is associated with the severity of IBS symptoms.[@b81-jnm-21-320] The gene polymorphism of *5-HTTLPR* is related to the development of IBS-D in females.[@b82-jnm-21-320] *5-HTTLPR* LS/SS genotype is also associated with both increased pain sensation and increased rectal compliance.[@b83-jnm-21-320] Serotonin is produced in the GI tract, brain, and neuronal cells, and is involved in GI motility and sensation. SERT regulates the amount of serotonin, and the S/S allele is associated with lower expression of SERT than the L/L allele, with serotonin absorption being half that of the L/L allele.[@b84-jnm-21-320] This gene is also called the anxiety gene, and the distribution of this gene allele is different among races. Japanese have a great predominance of the S/S allele compared to Caucasians. This may cause race-based differences in temperament. Therefore, it is important to realize that some gene polymorphisms are different in both pathophysiological conditions and races.

In FD, Holtmann et al[@b85-jnm-21-320] showed for the first time that *G-protein beta 3* (*GN*β*3*) C825T polymorphisms are related to the development of FD in 2004. The odds ratio for upper abdominal symptoms associated with the CC genotype was 2.2 compared with subjects with TC and TT genotype carrying an allele. Homozygous *GN*β*3* 825C carrier status is associated with unexplained predominantly upper abdominal symptoms. G-proteins are essential for stimulus-response coupling of receptors that are linked to intracellular effector systems. Approximately 80% of all known membrane receptors transduce their signals via heterotrimeric G-proteins. This polymorphism is known to affect many kinds of diseases, including hypertension. Camilleri et al[@b86-jnm-21-320] reported that meal-unrelated dyspepsia in a USA community study was associated with the homozygous 825T or C alleles of *GN*β*3*. We also analyzed this polymorphism in the Japanese population. Although *GN*β*3* C825T polymorphism was not associated with FD subjects overall, interestingly, the *GN*β*3* subunit 825TT genotype was associated with epigastric pain syndrome-like dyspepsia.[@b87-jnm-21-320] These data were consistent with the report that the *GN*β*3* subunit 825TT genotype was associated with FD without *Helicobacter pylori* infection in Japan.[@b88-jnm-21-320] Even in a report from The Netherlands, FD in the tertiary referral setting was associated with the 825T allele of the *GN*β*3* gene.[@b89-jnm-21-320] The *GN*β*3* C825T polymorphism has also been analyzed in patients with lower FGIDs, including IBS. However, no association has been shown in these diseases.[@b90-jnm-21-320]

We also analyzed the association between SERT gene (*SLC6A4*) polymorphism and FD. We found that the *5-HTTLPR* L allele affects susceptibility to PDS.[@b91-jnm-21-320] On the other hand, Camilleri et al[@b86-jnm-21-320] and van Lelyveld et al[@b89-jnm-21-320] did not show a relationship between SERT polymorphism and FD. These discrepancies may also be related to the difference in allele frequencies among races. In all FD, the CC genotype of *TRPV1*G315C polymorphism, and the gene polymorphisms of the tetrodotoxin resistant sodium channel NaV1.8, encoded by *SCN10A* were the only positive polymorphisms preventing the development of FD.[@b92-jnm-21-320],[@b93-jnm-21-320]

These data indicate that genetic factors are involved in the development of FGIDs. However, the odds ratio that can be acquired by these polymorphisms is maximally two to three. We need further evaluation of how these genetic factors and other circumstantial factors interact. Environmental factors affect their development. Children of mothers with IBS have more non-GI, as well as GI, symptoms.[@b94-jnm-21-320] When the parents have IBS, the risk of the development of IBS in their children is high, and the concordance between mothers and children was greater than the concordance between monozygotic twins,[@b75-jnm-21-320] indicating that not only genetic factors, but also parental behaviors affect their children.[@b95-jnm-21-320] Childhood abuse is associated with the development and exacerbation of IBS and the development of dyspepsia.[@b24-jnm-21-320],[@b96-jnm-21-320]--[@b98-jnm-21-320] These are also environmental factors related to the development of FGIDs.

Natural Course of Functional Gastrointestinal Disorders
=======================================================

As for the natural course of FD, the dyspeptic symptoms disappear in 50% of patients after several years.[@b4-jnm-21-320] Even in IBS patients, 40% of patients are not diagnosed as having IBS one year later.[@b27-jnm-21-320] Although the prevalences of FD and IBS were stable over 12--20 months, there was considerable turnover, with approximately half of those with FD and IBS on the first survey not having these symptoms on the second survey.[@b99-jnm-21-320] Another report using Rome II criteria also indicated that the proportion of subjects in a subgroup of IBS remained the same over a year, and more than 75% of subjects changed to either of the other 2 subtypes at least once.[@b100-jnm-21-320] IBS-M was the least stable diagnosis (only 4.9% remained in the original classification). Transitions between IBS-M and IBS-C were more likely than between IBS-D and IBS-M.

Halder et al[@b101-jnm-21-320] reported the natural history of FGIDs in a US population. In a prospective cohort followed for 12 years, approximately 20% had the same symptoms among people with symptoms at baseline, 40% had no symptoms, and 40% had different symptoms at follow-up. In uninvestigated dyspepsia, IBS-C, IBS-D, IBS-M, constipation, and diarrhea, the disappearance rate of each FGID between the initial and final surveys was 67%, 60%, 60%, 47%, 78%, and 71%, respectively. The feature that symptoms shift among FGIDs and disappear might also be characteristic of FGIDs.

In a large-scale survey in Japan, the symptoms of FD patients with symptoms at least twice a week regressed in one-third of patients after they were told that they had no organic disease based on examinations including endoscopy and of the pathophysio-logical basis of FD.[@b102-jnm-21-320] These data indicate that explanation of the condition to patients affects the symptoms of patients with FD, and that building a favorable doctor-patient relationship is effective for controlling symptoms of FD.

Conclusions
===========

It is well-known that FGIDs represent the most prevalent condition in patients who come to medical institutions with abdominal symptoms. Determining the etiology of these patients is important to establish the treatment strategy in the primary care setting.

Although the definitions of FGIDs can easily change their prevalence, there is no doubt that we often see FGID patients in the outpatient clinic. If we do not care for these patients appropriately, physicians and staff cannot establish good relationships with them, and patients will continue with doctor shopping. Regardless of the definition of FGID, physicians should explain the condition and ensure that patients have a satisfactory understanding of their disease.
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###### 

Prevalence of Fucntional Dyspepsia (Rome III Criteria)

  Study                                    Sample size   Subject group (Method of data collection)   Country      Age       Prevalence (%)   UD/FD (%)[^a^](#tfn1-jnm-21-320){ref-type="table-fn"}                                      
  ---------------------------------------- ------------- ------------------------------------------- ------------ --------- ---------------- ------------------------------------------------------- ----- ------ ------ ----- -------- ------
  Aro et al,[@b9-jnm-21-320] 2009          1001          GP (Postal)                                 Sweden       20--80    20.2             15.7                                                    5.2   12.2   \-     \-    13.5     26.5
  Barzkar et al,[@b10-jnm-21-320] 2009     18 180        GP (Interview)                              Iran         16--80    8.5              \-                                                      \-    \-     8.3    \-    6.1      10.9
  Kaji et al,[@b11-jnm-21-320] 2010        2680          Health check-up                             Japan        mean 40   10.0             \-                                                      \-    \-     14.2   3.4   \-       \-
  Noh et al,[@b12-jnm-21-320] 2010         2388          Health check-up                             Korea        mean 43   \-               8.1                                                     \-    \-     10.1   \-    \-       \-
  Zagari et al,[@b13-jnm-21-320] 2010      1033          GP (Postal)                                 Italy        32--84    15.1             11.0                                                    8.8   6.3    \-     \-    12.5     17.8
  Chang et al,[@b14-jnm-21-320] 2012       4275          GP (Interview)                              Taiwan       19 ≤      5.3              \-                                                      \-    \-     4.4    0.3   4.4      6.3
  Choung et al,[@b15-jnm-21-320] 2012      3517          GP (Postal)                                 USA          mean 61   9.8              \-                                                      \-    \-     19.4   5.2   6.2      12.8
  Mak et al,[@b16-jnm-21-320] 2012         2011          GP (Telephone)                              China        15--65    8.0              \-                                                      0.9   6.9    \-     \-    6.9      8.9
  Matsuzaki et al,[@b17-jnm-21-320] 2012   8038          GP (Internet)                               Japan        20--65    12.8             7.0                                                     2.3   6.2    \-     \-    6.6      7.3
  Miwa,[@b18-jnm-21-320] 2012              15 000        GP (Internet)                               Japan        20--79    6.5              \-                                                      \-    \-     14.0   3.0   M \< F   
  Kim et al,[@b19-jnm-21-320] 2014         3399          Health check-up                             Korea        15--98    \-               20.4                                                    9.5   13.9   \-     \-    17.5     24.0
  Min et al,[@b20-jnm-21-320] 2014         5000          GP (Telephone)                              Korea        20--69    7.7              \-                                                      4.2   5.6    3.5    1.9   5.9      9.5
  Perveen et al,[@b21-jnm-21-320] 2014     3000          GP (Interview)                              Bangladesh   15--97    8.3              \-                                                      6.0   6.8    12.9   3.5   8.7      8.0
  Rasmussen et al,[@b22-jnm-21-320] 2014   47 090        GP (Internet)                               Denmark      20 ≤      7.7              \-                                                      \-    \-     10.5   2.9   6.4      8.8

Prevalence in male (M) and female (F) (%), including the calculated data from papers.

UD, uninvestigated dyspepsia; FD, functional dyspepsia; EPS, epigastric pain syndrome; PDS, postprandial distress syndrome; GP, general population; -, not assessed.

###### 

Prevalence of Irritable Bowel Syndrome (Rome III Criteria)

  Study                                                                                    Sample size   Subject group (Method of data collection)   Country      Age       IBS (%)[^a^](#tfn3-jnm-21-320){ref-type="table-fn"}   Subtype (%)[^a^](#tfn3-jnm-21-320){ref-type="table-fn"}                            
  ---------------------------------------------------------------------------------------- ------------- ------------------------------------------- ------------ --------- ----------------------------------------------------- --------------------------------------------------------- ------ ----- ----- ----- -----
  Jung et al,[@b28-jnm-21-320] 2007                                                        2273          GP (Postal)                                 USA          33--93    11.1                                                  7.9                                                       13.9   3.2   3.9   1.3   2.7
  Miwa,[@b29-jnm-21-320] 2008                                                              10 000        GP (Internet)                               Japan        20 ≤      13.1                                                  10.7                                                      15.5   3.1   3.9   6.1   \-
  Gomez Alvarez et al,[@b30-jnm-21-320] 2009[^b^](#tfn4-jnm-21-320){ref-type="table-fn"}   558           GP (Interview)                              Colombia     18--60    19.9                                                  \-                                                        \-     \-    \-    \-    \-
  Khoshkrood-Mansoori et al,[@b31-jnm-21-320] 2009                                         18 180        GP (Interview)                              Iran         16 ≤      1.1                                                   0.6                                                       1.5    \-    \-    \-    \-
  Lee et al,[@b32-jnm-21-320] 2009                                                         2005          GP (Telephone)                              China        15--65    5.4                                                   4.6                                                       6.2    1.1   2.0   0.3   1.9
  Kaji et al,[@b11-jnm-21-320] 2010                                                        2680          Health check-up                             Japan        Mean 40   14.2                                                  \-                                                        \-     \-    \-    \-    \-
  Noh et al,[@b12-jnm-21-320] 2010                                                         2388          Health check-up                             Korea        Mean 43   10.1                                                  \-                                                        \-     \-    \-    \-    \-
  Sorouri et al,[@b33-jnm-21-320] 2010                                                     18 180        GP (Interview)                              Iran         16--80    1.1                                                   0.6                                                       1.5    \-    \-    \-    \-
  Ebling et al,[@b34-jnm-21-320] 2011                                                      703           GP (Postal)                                 Croatia      20--69    29.2                                                  21.4                                                      36.7   \-    \-    \-    \-
  Kubo et al,[@b35-jnm-21-320] 2011                                                        2717          Health check-up                             Japan        Mean 40   13.5                                                  10.5                                                      19.3   2.9   3.8   3.3   3.6
  Makharia et al,[@b36-jnm-21-320] 2011                                                    4767          GP (Interview)                              India        18--64    4.0                                                   3.2                                                       4.8    0.3   1.5   1.7   0.5
  Chang et al,[@b14-jnm-21-320] 2012                                                       4275          GP (Interview)                              Taiwan       19 ≤      4.4                                                   3.4                                                       5.4    \-    \-    \-    \-
  Choung et al,[@b15-jnm-21-320] 2012                                                      3517          GP (Postal)                                 USA          Mean 61   19.4                                                  \-                                                        \-     \-    \-    \-    \-
  Miwa,[@b18-jnm-21-320] 2012                                                              15 000        GP (Internet)                               Japan        20--79    14.0                                                  12.7                                                      15.4   \-    \-    \-    \-
  Krogsgaard et al,[@b37-jnm-21-320] 2013                                                  6112          GP (Internet)                               Denmark      18--50    16.0                                                  M \< F                                                    2.9    5.3   5.7   1.8   
  Lin et al,[@b38-jnm-21-320] 2014                                                         1002          GP (Interview)                              UK           16--93    6.0                                                   M \< F                                                    0.7    1.4   2.7   1.2   
  Perveen et al,[@b21-jnm-21-320] 2014                                                     3000          GP (Interview)                              Bangladesh   15--97    12.9                                                  12.4                                                      13.6   3.5   4.5   3.7   0.6
  Rasmussen et al,[@b22-jnm-21-320] 2014                                                   47 090        GP (Internet)                               Denmark      20 ≤      10.5                                                  7.9                                                       12.8   \-    \-    \-    \-

Including the calculated data from papers,

Spanish (English abstract).

IBS, irritable bowel syndrome; M, male; F, female; IBS-C, IBS with constipation; IBS-D, IBS with diarrhea IBS-M, mixed IBS; IBS-U, unsubtyped IBS; GP, general population; -, not assessed.

###### 

Prevalence of Functional Gastrointestinal Dyspepsia (Rome III Criteria)

  Study                                  Sample size   Subject group (Method of data collection)   Country   Age      PrevalenceTotal (M/F) (%)                                                                                     
  -------------------------------------- ------------- ------------------------------------------- --------- -------- --------------------------- --------------- --------------- --------------- --------------- ----------------- ---------------
  Sorouri et al,[@b33-jnm-21-320] 2010   18 180        GP (Interview)                              Iran      16--80   8.9(−/−)                    1.1(0.6/1.5)    1.5 (1.4/1.7)   2.4 (1.2/3.7)   0.2(0.2/0.3)    5.5(4.3/6.7)      \-
  Chang et al,[@b14-jnm-21-320] 2012     4275          GP (Interview)                              Taiwan    19 ≤     5.3 (4.4/6.3)               4.4 (3.4/5.4)   2.1 (1.3/3.0)   4.4 (2.8/6.2)   2.2 (2.7/1.7)   8.9 (7.6 /10.2)   0.4 (0.2/0.5)

M, male; F, female; UD, uninvestigated dyspepsia; IBS, irritable bowel syndrome; AB, abdominal bloating UBD, unspecified bowel disorder; APS, abdominal pain syndrome; GP, general population; -, not assessed.
